Table 1.

Summary of clinical trial results with HSV vaccine candidates

Name	Platform	Antigens	Immune Response	Clinical Results
gB/gD/MF59 (Chiron)	Subunit MF59 adjuvant	gD and gB	Neutralizing Abs	Phase 3 Prophylaxis 9% (95% CI: −29%, 36%)
gD/AS04 (GSK)	Subunit AS04 adjuvant	gD	Neutralizing Abs CD4+ T cells	Phase 3 Prophylaxis 20% (95% CI: −29%, 50%)
gH-null (Cantab Pharmaceuticals)	Single-cycle live	Multiple	Neutralizing Abs	Phase 3 therapeutic No difference in recurrences or shedding
HSV529 (Sanofi-Pasteur)	Replication-defective	Multiple	Neutralizing Abs CD4, CD8 T cells	Phase 1 Safe but immunogenic in doubly-seronegatives only
Gen-003 (Genocea)	Subunit Saponin adjuvant	gD, ICP4	Neutralizing Abs Cytolytic T cells	Phase 2 therapeutic Dose variable decrease shedding
HerpV (Agenus)	Heat shock protein 70-HSV peptides QS-21 adjuvant	32 HSV peptides (gD, additional envelope, tegument, and other)	Cytotoxic T cells	Phase 2 therapeutic 17% reduction in shedding frequency
Vaxfectin (Vical)	DNA Vaxfectin adjuvant	gD, UL46/47	Neutralizing Abs	Phase 1/2 therapeutic Failed to reduce shedding
COR-1 (Admedus)	Codon optimized DNA	Codon optimized gD2 and ubiquitin-fused truncated gD2 to target the antigen to the proteasome	gD-specific Abs Cytotoxic T cells	Phase 2 therapeutic No difference in recurrences
ΔNLS (Rational Vaccines)	Deleted in ICP0 Replication competent Attenuated for latency	Multiple targets	Neutralizing Abs gD-specific Abs	Phase 1 non-FDA approved therapeutic study Self-reported reduction in recurrences